MedTrace Logo

Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

NCT02605174 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3005

Last updated 2019-09-23

Study results available
· View outcomes & findings →

Summary

This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).

Conditions

  • Migraine With or Without Aura

Interventions

DRUG

Lasmiditan 50 mg

One tablet lasmiditan 50 mg plus one placebo tablet (matching one of the lasmiditan doses)

DRUG

Lasmiditan 100 mg

One tablet lasmiditan 100 mg plus one placebo tablet (matching one of the lasmiditan doses)

DRUG

Lasmiditan 200 mg

One tablet lasmiditan 200 mg plus one placebo tablet (matching one of the lasmiditan doses)

DRUG

Placebo

Two placebo tablets to match lasmiditan doses.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02605174 on ClinicalTrials.gov